Leading the Way in Life Science Technologies

GEN Exclusives

More »

Feature Articles

More »

For full access to this article login to GEN Select now.

January 15, 2009 (Vol. 29, No. 2)

Japanese BioAlliance Strategies Evolving

Changes Are Necessary as Collaborations with U.S. Firms Often Run into Cultural Roadblocks

  • Significant transformations are occurring within Japan’s leading pharmaceutical companies as they consider strategic alternatives to doing business in the U.S. Traditionally, Japanese companies, other than the four largest—Takeda, Daiichi Sankyo, Astellas, and Eisai, have focused on two major types of strategic transactions: in-licensing or acquiring a compound for the ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.